AstraZeneca UK Limited
$124.7M 2,367 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. reported $123,464,722.93 across General Payments, Research, and Ownership to 5,932 physicians and teaching hospitals across 36,508 transactions.
- $123.5M Top 1% payer
- All-tracks total
- 36,508 Top 10% volume
- Transactions
- 5,932 Top quartile reach
- Recipients
- −$642.0K
- General Payments vs PY2023
Regeneron Pharmaceuticals, Inc. reported $123,464,722.93 across all CMS Open Payments tracks (General + Research + Ownership) to 5,932 physicians and teaching hospitals in Program Year 2024 - ranking #20 of 1,925 reporting manufacturers (0.9% of the all-tracks industry total); General Payments alone were $9,115,877.17, averaging $20.8K per recipient.
How Regeneron Pharmaceuticals, Inc.'s $123.5M all-tracks total breaks down
Regeneron Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
B
89/100
Total payments
A
100/100
Transaction volume
A
100/100
Physician reach
D
55/100
Payment type diversity
A
100/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer regeneron-pharmaceuticals-inc Regeneron Pharmaceuticals, Inc.
$123.5M · #20/1,925 · 0.9% industry · PY2024
- TOT $123.5M
- RANK #20
- SHARE 0.9%
- TXN 36,508
- RCP 5,932
- CAT 9
- GEN $9.1M
- ΔGEN −$642.0K
- TOP1 9.7%
- PY 2024
Volume peers
Nearest volume peer: AstraZeneca UK Limited ($124.7M)
Regeneron Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Regeneron Pharmaceuticals, Inc.'s CMS-reported General Payments decreased by $642.0K (−6.6%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: REGENERON PHARMACEUTICALS, INC.PY2023: REGENERON PHARMACEUTICALS, INC.PY2024: Regeneron Pharmaceuticals, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $9,757,861.29
- PY2024
- $9,115,877.17
What the Data Shows for Regeneron Pharmaceuticals, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Regeneron Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
The 9-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $6.6M, accounting for 72.1% of this company's General Payments and 1,877 transactions.
General Payment Breakdown by Type
"Consulting Fee" leads Regeneron Pharmaceuticals, Inc.'s 9-category general-payment breakdown at $6.6M, 72.1% of the reported total.
Regeneron Pharmaceuticals, Inc. reports 9 general-payment categories - the top three are Consulting Fee (72.1%), Travel and Lodging (8.9%), and Grant (6.5%). The remaining 6 categories make up 12.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Regeneron Pharmaceuticals, Inc. files across 9 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Regeneron Pharmaceuticals, Inc. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $6.6M | 1,877 | 72.1% |
| Travel and Lodging | $815.0K | 1,287 | 8.9% |
| Grant | $593.9K | 59 | 6.5% |
| Royalty or License | $536.0K | 38 | 5.9% |
| Space Rental or Facility Fees | $375.4K | 21 | 4.1% |
| Food and Beverage | $202.1K | 2,612 | 2.2% |
| Compensation for Services Other Than Consulting | $12.5K | 1 | 0.1% |
| Education | $6.9K | 11 | 0.1% |
| Charitable Contribution | $5.2K | 26 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $3,628,787.33 (39.8%) of $9,115,877.17 in this company's General Payments records across 1,654 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Regeneron Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Huda Zoghbi
$881,253.04 across 56 reported transactions
- 2
Joseph Leonard Goldstein
$829,671.28 across 64 reported transactions
- 3
Michael S Brown
$825,173.28 across 69 reported transactions
- 4
Craig Thompson
$707,320.21 across 40 reported transactions
- 5
Ronald Reagan Ucla
$385,369.52 across 23 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Regeneron Pharmaceuticals, Inc. ranks #20 of 1,925 by total payments (top 1% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,397 of 1,838 by HHI (bottom 24% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- XVIVO Perfusion Inc. : $51.8K total payments, HHI 377
- Carl Zeiss Meditec, Inc. : $938.6K total payments, HHI 376
- CDC Medical LLC : $22.6K total payments, HHI 376
- Gynesonics, Inc. : $1.1M total payments, HHI 375
- BioCryst US Sales Co., LLC : $658.2K total payments, HHI 374
- Janssen Research & Development, LLC : $4.7M total payments, HHI 372
- Regeneron Pharmaceuticals, Inc. (this company) : $9.1M total payments, HHI 371
- Paragon 28, Inc. : $3.4M total payments, HHI 370
- Sonio : $192.5K total payments, HHI 370
- Visioneering Technologies, Inc. : $417.3K total payments, HHI 369
- Veloxis Pharmaceuticals, Inc. : $89.2K total payments, HHI 365
- Hiossen, Inc. : $2.4M total payments, HHI 364
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Regeneron Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Regeneron Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Regeneron Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Sanofi US Services Inc.
$114.0M 478 recipients
Compare payment profiles
Edge Endo LLC
$113.4M 40 recipients
Compare payment profiles
Trimed, Inc.
$111.0M 2,318 recipients
Compare payment profiles
Vertex Pharmaceuticals Incorporated
$109.6M 10,996 recipients
Compare payment profiles
Arthrex, Inc.
$109.0M 49,842 recipients
Compare payment profiles
Put this to use
Regeneron Pharmaceuticals, Inc. ranks #20 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Regeneron Pharmaceuticals, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Regeneron Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.